세계의 분자진단 시장 - 규모, 점유율, 동향 분석 보고서 : 제품별, 검사 부위별, 기술별, 용도별, 지역별, 부문 예측(2025-2030년)

Molecular Diagnostics Market Growth & Trends:

The global molecular diagnostics market size is estimated to reach USD 33.08 billion by 2030, expanding at a CAGR of 3.97% from 2025 to 2030, according to a new report by Grand View Research, Inc. The contraction in the market will be due to the decline in demand for molecular testing for COVID-19. However, factors such as the rising geriatric population and increasing demand for technologies such as NGS is expected to drive market growth.

Molecular diagnostics plays an important role in infectious disease testing as they can yield effective and fast results. Hence, the increasing prevalence of hospital-acquired infections & infectious diseases is projected to drive the market over the forecast period. Increasing incidence and awareness regarding genetic disorders is further anticipated to accelerate market growth. The miniaturization of three basic molecular assays-nanobiotechnology, biochips, and microfluidics are expected to increase the accuracy and specificity of diagnostic outcomes, and hence, increase the demand for molecular diagnostic products. These improvements are expected to enhance the availability of PoC molecular diagnostic tests to yield quick and effective test results.

Companies are expanding their product portfolios with the acquisition of smaller companies. For instance, in March 2021, Hologic announced the acquisition of Diagenode-a molecular diagnostic company with a wide range of PCR instruments, facilitating the detection of over 30 bacteria-for USD 159 million. Similarly, in April 2021, F. Hoffmann-La Roche Ltd. acquired GenMark Diagnostics, Inc. at a price of USD 24.05 per share in cash, and it holds around 82.89% of total shares of GenMark Diagnostics. GenMark Diagnostics, Inc. has proprietary technologies, such as eSensor XT-8 and ePlex, which can be utilized in developing tests for infectious diseases, including bloodstream infections.

Key players are enhancing their range of testing options for real-time PCR instruments by increasing R&D activities for the development of kits that target emerging diseases or by entering into agreements with other kit manufacturing companies. These include the introduction of Cobas HPV test assay in Cobas 4800 by Roche Diagnostics. The introduction of tuberculosis testing Xpert assay on GeneXpert platform by Cepheid is an example of such advancement. Such advances are anticipated to drive the global molecular diagnostics market.

Molecular Diagnostics Market Report Highlights:

• The reagents segment dominated the market and accounted for a share of 65.44% of the global revenue in 2024. It is expected to maintain its dominance throughout the forecast years owing to its wide application scope in research & clinical settings and increasing adoption of novel tests.
• The polymerase chain reaction technology segment accounted for the largest revenue share in 2024. This is attributed to its use in detecting COVID-19 and other infectious diseases.
• The infectious diseases segment accounted for the largest revenue share in 2024. The increased usage of molecular, particularly PCR tests, for diagnosing COVID-19 has increased the segment share significantly.
• The central laboratories segment dominated the industry in 2024 owing to high procedure volumes for COVID testing and other healthcare indications in central laboratories.
• North America dominated the market and accounted for a 40.95% share in 2024. This is attributed to the rising epidemiology of infectious as well as chronic diseases, thus, encouraging companies to introduce novel molecular diagnostic tests, thereby boosting market growth.
• Asia Pacific is anticipated to exhibit significant growth from 2025 to 2030 owing to increased market penetration, initiatives of local market players to increase the adoption of novel diagnostic technologies, and high unmet market needs.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. End Use
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Molecular Diagnostics Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increase in geriatric population
    • 3.2.1.2. Introduction of technologically advanced products
    • 3.2.1.3. Increase in demand for point-of-care Testing
    • 3.2.1.4. Growing prevalence of target diseases
    • 3.2.1.5. Increasing external funding for R&D
    • 3.2.1.6. Outbreak of COVID-19
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Presence of ambiguous regulatory framework
    • 3.2.2.2. High prices of molecular diagnostics tests
• 3.3. Molecular Diagnostics Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Molecular Diagnostics Market: Segment Analysis, By Product, 2018 - 2030 (USD Million)

• 4.1. Definition and Scope
• 4.2. Product Market Share Analysis, 2024 & 2030
• 4.3. Molecular Diagnostics Market, by Product, 2018 to 2030
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 4.4.1. Instruments
    • 4.4.1.1. Instruments market, 2018 - 2030 (USD Million)
  • 4.4.2. Reagents
    • 4.4.2.1. Reagents market, 2018 - 2030 (USD Million)
  • 4.4.3. Others
    • 4.4.3.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Molecular Diagnostics Market: Segment Analysis, By Test Location, 2018 - 2030 (USD Million)

• 5.1. Definition and Scope
• 5.2. Test Location Market Share Analysis, 2024 & 2030
• 5.3. Global Molecular Diagnostics Market, by Test Location, 2018 to 2030
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 5.4.1. Point of care
    • 5.4.1.1. Point of care market, 2018 - 2030 (USD Million)
  • 5.4.2. Self test or OTC
    • 5.4.2.1. Self test or OTC market, 2018 - 2030 (USD Million)
  • 5.4.3. Central laboratories
    • 5.4.3.1. Central laboratories market, 2018 - 2030 (USD Million)

Chapter 6. Molecular Diagnostics Market: Segment Analysis, By Technology, 2018 - 2030 (USD Million)

• 6.1. Definition and Scope
• 6.2. Technology Market Share Analysis, 2024 & 2030
• 6.3. Global Molecular Diagnostics Market, by Technology, 2018 to 2030
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 6.4.1. PCR
    • 6.4.1.1. PCR market, 2018 - 2030 (USD Million)
    • 6.4.1.2. By procedure
      • 6.4.1.2.1. Nucleic acid extraction
        • 6.4.1.2.1.1. Nucleic acid extraction market, 2018 - 2030 (USD Million)
      • 6.4.1.2.2. Others
        • 6.4.1.2.2.1. Others market, 2018 - 2030 (USD Million)
    • 6.4.1.3. By type
      • 6.4.1.3.1. Multiplex
        • 6.4.1.3.1.1. Multiplex market, 2018 - 2030 (USD Million)
      • 6.4.1.3.2. Others
        • 6.4.1.3.2.1. Others market, 2018 - 2030 (USD Million)
    • 6.4.1.4. By product
      • 6.4.1.4.1. Instruments
        • 6.4.1.4.1.1. Instruments market, 2018 - 2030 (USD Million)
      • 6.4.1.4.2. Reagents
        • 6.4.1.4.2.1. Reagents market, 2018 - 2030 (USD Million)
      • 6.4.1.4.3. Others
        • 6.4.1.4.3.1. Others market, 2018 - 2030 (USD Million)
  • 6.4.2. ISH
    • 6.4.2.1. ISH market, 2018 - 2030 (USD Million)
    • 6.4.2.2. Instruments
      • 6.4.2.2.1. Instruments market, 2018 - 2030 (USD Million)
    • 6.4.2.3. Reagents
      • 6.4.2.3.1. Reagents market, 2018 - 2030 (USD Million)
    • 6.4.2.4. Others
      • 6.4.2.4.1. Others market, 2018 - 2030 (USD Million)
  • 6.4.3. INAAT
    • 6.4.3.1. INAAT market, 2018 - 2030 (USD Million)
    • 6.4.3.2. Instruments
      • 6.4.3.2.1. Instruments market, 2018 - 2030 (USD Million)
    • 6.4.3.3. Reagents
      • 6.4.3.3.1. Reagents market, 2018 - 2030 (USD Million)
    • 6.4.3.4. Others
      • 6.4.3.4.1. Others market, 2018 - 2030 (USD Million)
  • 6.4.4. Chips and microarrays
    • 6.4.4.1. Chips and microarrays market, 2018 - 2030 (USD Million)
    • 6.4.4.2. Instruments
      • 6.4.4.2.1. Instruments market, 2018 - 2030 (USD Million)
    • 6.4.4.3. Reagents
      • 6.4.4.3.1. Reagents market, 2018 - 2030 (USD Million)
    • 6.4.4.4. Others
      • 6.4.4.4.1. Others market, 2018 - 2030 (USD Million)
  • 6.4.5. Mass spectrometry
    • 6.4.5.1. Mass spectrometry market, 2018 - 2030 (USD Million)
    • 6.4.5.2. Instruments
      • 6.4.5.2.1. Instruments market, 2018 - 2030 (USD Million)
    • 6.4.5.3. Reagents
      • 6.4.5.3.1. Reagents market, 2018 - 2030 (USD Million)
    • 6.4.5.4. Others
      • 6.4.5.4.1. Others market, 2018 - 2030 (USD Million)
  • 6.4.6. Sequencing
    • 6.4.6.1. Sequencing market, 2018 - 2030 (USD Million)
    • 6.4.6.2. Instruments
      • 6.4.6.2.1. Instruments market, 2018 - 2030 (USD Million)
    • 6.4.6.3. Reagents
      • 6.4.6.3.1. Reagents market, 2018 - 2030 (USD Million)
    • 6.4.6.4. Others
      • 6.4.6.4.1. Others market, 2018 - 2030 (USD Million)
  • 6.4.7. TMA
    • 6.4.7.1. TMA market, 2018 - 2030 (USD Million)
    • 6.4.7.2. Instruments
      • 6.4.7.2.1. Instruments market, 2018 - 2030 (USD Million)
    • 6.4.7.3. Reagents
      • 6.4.7.3.1. Reagents market, 2018 - 2030 (USD Million)
    • 6.4.7.4. Others
      • 6.4.7.4.1. Others market, 2018 - 2030 (USD Million)
  • 6.4.8. Others
    • 6.4.8.1. Others market, 2018 - 2030 (USD Million)
    • 6.4.8.2. Instruments
      • 6.4.8.2.1. Instruments market, 2018 - 2030 (USD Million)
    • 6.4.8.3. Reagents
      • 6.4.8.3.1. Reagents market, 2018 - 2030 (USD Million)
    • 6.4.8.4. Others
      • 6.4.8.4.1. Others market, 2018 - 2030 (USD Million)

Chapter 7. Molecular Diagnostics Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

• 7.1. Definition and Scope
• 7.2. Application Market Share Analysis, 2024 & 2030
• 7.3. Global Molecular Diagnostics Market, by Application,2018 to 2030
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 7.4.1. Oncology
    • 7.4.1.1. Oncology market, 2018 - 2030 (USD Million)
    • 7.4.1.2. Breast cancer
      • 7.4.1.2.1. Breast cancer market, 2018 - 2030 (USD Million)
    • 7.4.1.3. Prostate cancer
      • 7.4.1.3.1. Prostate cancer market, 2018 - 2030 (USD Million)
    • 7.4.1.4. Colorectal cancer
      • 7.4.1.4.1. Colorectal cancer market, 2018 - 2030 (USD Million)
    • 7.4.1.5. Cervical
      • 7.4.1.5.1. Cervical market, 2018 - 2030 (USD Million)
    • 7.4.1.6. Kidney
      • 7.4.1.6.1. Kidney market, 2018 - 2030 (USD Million)
    • 7.4.1.7. Liver
      • 7.4.1.7.1. Liver market, 2018 - 2030 (USD Million)
    • 7.4.1.8. Blood
      • 7.4.1.8.1. Blood market, 2018 - 2030 (USD Million)
    • 7.4.1.9. Lung
      • 7.4.1.9.1. Lung market, 2018 - 2030 (USD Million)
    • 7.4.1.10. Other
      • 7.4.1.10.1. Other market, 2018 - 2030 (USD Million)
  • 7.4.2. Pharmacogenomics
    • 7.4.2.1. Pharmacogenomics market, 2018 - 2030 (USD Million)
  • 7.4.3. Infectious disease
    • 7.4.3.1. Infectious disease market, 2018 - 2030 (USD Million)
    • 7.4.3.2. MRSA
      • 7.4.3.2.1. MRSA market, 2018 - 2030 (USD Million)
    • 7.4.3.3. Clostridium difficile
      • 7.4.3.3.1. Clostridium difficile market, 2018 - 2030 (USD Million)
    • 7.4.3.4. Vancomycin-resistant enterococci
      • 7.4.3.4.1. Vancomycin-resistant enterococci market, 2018 - 2030 (USD Million)
    • 7.4.3.5. Carbapenem-resistant bacteria testing
      • 7.4.3.5.1. Carbapenem-resistant bacteria testing market, 2018 - 2030 (USD Million)
    • 7.4.3.6. Flu
      • 7.4.3.6.1. Flu market, 2018 - 2030 (USD Million)
    • 7.4.3.7. Respiratory syncytial virus (RSV)
      • 7.4.3.7.1. Respiratory syncytial virus (RSV) market, 2018 - 2030 (USD Million)
    • 7.4.3.8. Candida
      • 7.4.3.8.1. Candida market, 2018 - 2030 (USD Million)
    • 7.4.3.9. Tuberculosis and drug-resistant TB
      • 7.4.3.9.1. Tuberculosis and drug-resistant TB market, 2018 - 2030 (USD Million)
    • 7.4.3.10. Meningitis
      • 7.4.3.10.1. Meningitis market, 2018 - 2030 (USD Million)
    • 7.4.3.11. Gastro-intestinal panel testing
      • 7.4.3.11.1. Gastro-intestinal panel testing market, 2018 - 2030 (USD Million)
    • 7.4.3.12. Chlamydia
      • 7.4.3.12.1. Chlamydia market, 2018 - 2030 (USD Million)
    • 7.4.3.13. Gonorrhea
      • 7.4.3.13.1. Gonorrhea market, 2018 - 2030 (USD Million)
    • 7.4.3.14. HIV
      • 7.4.3.14.1. HIV market, 2018 - 2030 (USD Million)
    • 7.4.3.15. Hepatitis C
      • 7.4.3.15.1. Hepatitis C market, 2018 - 2030 (USD Million)
    • 7.4.3.16. Hepatitis B
      • 7.4.3.16.1. Hepatitis B market, 2018 - 2030 (USD Million)
    • 7.4.3.17. Other infectious diseases
      • 7.4.3.17.1. Other infectious diseases market, 2018 - 2030 (USD Million)
  • 7.4.4. Genetic testing
    • 7.4.4.1. Genetic testing market, 2018 - 2030 (USD Million)
    • 7.4.4.2. Newborn screening
      • 7.4.4.2.1. Newborn screening market, 2018 - 2030 (USD Million)
    • 7.4.4.3. Predictive and presymptomatic testing
      • 7.4.4.3.1. Predictive and presymptomatic testing market, 2018 - 2030 (USD Million)
    • 7.4.4.4. Others
      • 7.4.4.4.1. Others market, 2018 - 2030 (USD Million)
  • 7.4.5. Neurological disease
    • 7.4.5.1. Neurological disease market, 2018 - 2030 (USD Million)
  • 7.4.6. Cardiovascular disease
    • 7.4.6.1. Cardiovascular disease market, 2018 - 2030 (USD Million)
  • 7.4.7. Microbiology
    • 7.4.7.1. Microbiology market, 2018 - 2030 (USD Million)
  • 7.4.8. Others
    • 7.4.8.1. Others market, 2018 - 2030 (USD Million)

Chapter 8. Molecular Diagnostics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.4. Spain
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.6. Belgium
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Belgium market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.7. Switzerland
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Switzerland market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.8. Netherlands
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Netherlands market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.9. Poland
    • 8.4.9.1. Key country dynamics
    • 8.4.9.2. Regulatory framework/ reimbursement structure
    • 8.4.9.3. Competitive scenario
    • 8.4.9.4. Poland market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.10. Austria
    • 8.4.10.1. Key country dynamics
    • 8.4.10.2. Regulatory framework/ reimbursement structure
    • 8.4.10.3. Competitive scenario
    • 8.4.10.4. Austria market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.11. Denmark
    • 8.4.11.1. Key country dynamics
    • 8.4.11.2. Regulatory framework/ reimbursement structure
    • 8.4.11.3. Competitive scenario
    • 8.4.11.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.12. Sweden
    • 8.4.12.1. Key country dynamics
    • 8.4.12.2. Regulatory framework/ reimbursement structure
    • 8.4.12.3. Competitive scenario
    • 8.4.12.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.13. Turkey
    • 8.4.13.1. Key country dynamics
    • 8.4.13.2. Regulatory framework/ reimbursement structure
    • 8.4.13.3. Competitive scenario
    • 8.4.13.4. Turkey market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.4.14. Norway
    • 8.4.14.1. Key country dynamics
    • 8.4.14.2. Regulatory framework/ reimbursement structure
    • 8.4.14.3. Competitive scenario
    • 8.4.14.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. China
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.5. Thailand
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.6. Sri Lanka
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Sri Lanka market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.7. Malaysia
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework/ reimbursement structure
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Malaysia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.8. Vietnam
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Regulatory framework/ reimbursement structure
    • 8.5.8.3. Competitive scenario
    • 8.5.8.4. Vietnam market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5.9. Singapore
    • 8.5.9.1. Key country dynamics
    • 8.5.9.2. Regulatory framework/ reimbursement structure
    • 8.5.9.3. Competitive scenario
    • 8.5.9.4. Singapore market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.2. Colombia
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Colombia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.3. Chile
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Chile market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.4. Peru
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Peru market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6.5. Argentina
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.3. Jordan
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. Jordan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.5. Qatar
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. Qatar market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.6. Egypt
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ reimbursement structure
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Egypt market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7.7. Kuwait
    • 8.7.7.1. Key country dynamics
    • 8.7.7.2. Regulatory framework/ reimbursement structure
    • 8.7.7.3. Competitive scenario
    • 8.7.7.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Recent Developments & Impact Analysis by Key Market Participants
• 9.3. Company Market Share Analysis, 2024
• 9.4. Key Company Profiles
  • 9.4.1. BD
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. BIOMERIEUX
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Bio-Rad Laboratories, Inc.
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Abbott
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Agilent Technologies, Inc.
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Danaher
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Hologic Inc. (Gen Probe)
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Illumina, Inc.
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Grifols
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. QIAGEN
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. F. Hoffmann-La Roche, Ltd.
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Product benchmarking
    • 9.4.11.4. Strategic initiatives
  • 9.4.12. Siemens Healthineers AG
    • 9.4.12.1. Company overview
    • 9.4.12.2. Financial performance
    • 9.4.12.3. Product benchmarking
    • 9.4.12.4. Strategic initiatives
  • 9.4.13. Sysmex Corporatio